Skip to main content
Erschienen in: Clinical and Translational Oncology 7/2020

25.11.2019 | Research Article

Constitutive expression of c-REL in uveal melanoma patients: correlation with clinicopathological parameters and patient outcome

verfasst von: M. K. Singh, L. Singh, N. Pushker, K. Chosdol, S. Bakhshi, R. Meel, S. Sen, S. Kashyap

Erschienen in: Clinical and Translational Oncology | Ausgabe 7/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Uveal melanoma (UM) is the most common intraocular cancer with a high mortality rate that requires new research in the field of prevention and treatment. c-REL is a member of the nuclear factor κB (NF-κB) transcription factor family and an emerging regulator of tumorigenesis. Therefore, the objective of the study is to evaluate the constitutive expression of c-REL in uveal melanoma patients and its prognostic significance.

Methods

Detection of c-REL expression was carried out by immunohistochemistry in all 75 patients, and qRT-PCR performed on 58 fresh cases of uveal melanoma along with IL-6 status. Immunoblot was performed to validate immunohistochemistry results. Expression of c-REL protein correlated with clinicopathological parameters and overall survival of patients.

Results

Immunohistochemistry results revealed nuclear expression of the c-REL protein (56%) in our cases. Out of 75 cases, 31 cases showed nuclear expression, and 11 cases had cytoplasmic expression. qRT-PCR showed upregulation of the REL gene in 56.89% cases at the transcriptional level. There was a statistically significant difference in the overall survival of patients with c-REL nuclear immunopositivity (p = 0.0048). On multivariate analysis, scleral invasion and c-REL nuclear expression found to be an independent prognostic factor (p < 0.05)

Conclusions

To the best of our knowledge, this was the first study reporting the expression of the c-REL protein in uveal melanoma. Strong nuclear immunoexpression of c-Rel suggests NFκB pathway activation which might be involved in the progression of the disease. Differential expression of c-REL protein may be used as an attractive target for the development of anticancer strategies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Amaro A, Gangemi R, Piaggio F, et al. The biology of uveal melanoma. Cancer Metastasis Rev. 2017;36:109–40.CrossRef Amaro A, Gangemi R, Piaggio F, et al. The biology of uveal melanoma. Cancer Metastasis Rev. 2017;36:109–40.CrossRef
2.
Zurück zum Zitat Nathan P, Cohen V, Coupland S, et al. United Kingdom Uveal Melanoma Guideline Development Working Group. Eur J Cancer. 2015;51:2404–12.CrossRef Nathan P, Cohen V, Coupland S, et al. United Kingdom Uveal Melanoma Guideline Development Working Group. Eur J Cancer. 2015;51:2404–12.CrossRef
3.
Zurück zum Zitat Diener-West M, Reynolds SM, Agugliaro DJ, et al. Collaborative Ocular Melanoma Study Group Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: collaborative ocular melanoma study group report no. 26. Arch Ophthalmol. 2005;123: 1639–1643. Diener-West M, Reynolds SM, Agugliaro DJ, et al. Collaborative Ocular Melanoma Study Group Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: collaborative ocular melanoma study group report no. 26. Arch Ophthalmol. 2005;123: 1639–1643.
4.
Zurück zum Zitat Rietschel P, Panageas KS, Hanlon C, et al. Variates of survival in metastatic uveal melanoma. J Clin Oncol. 2005;23:7576.CrossRef Rietschel P, Panageas KS, Hanlon C, et al. Variates of survival in metastatic uveal melanoma. J Clin Oncol. 2005;23:7576.CrossRef
5.
Zurück zum Zitat Damato B. Does ocular treatment of uveal melanoma influence survival? Br J Cancer. 2010;103:285–90.CrossRef Damato B. Does ocular treatment of uveal melanoma influence survival? Br J Cancer. 2010;103:285–90.CrossRef
6.
Zurück zum Zitat Li Q, Verma IM. NF-κB regulation in the immune system. Nat Rev Immunol. 2002;2:725–34.CrossRef Li Q, Verma IM. NF-κB regulation in the immune system. Nat Rev Immunol. 2002;2:725–34.CrossRef
7.
Zurück zum Zitat Karin M, Cao Y, Greten FR, Li ZW. NF-kB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301–10.CrossRef Karin M, Cao Y, Greten FR, Li ZW. NF-kB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301–10.CrossRef
8.
Zurück zum Zitat Ben-Neriah Y, Karin M. Inflammation meets cancer, with NFkappaB as the matchmaker. Nat Immunol. 2011;12:715–23.CrossRef Ben-Neriah Y, Karin M. Inflammation meets cancer, with NFkappaB as the matchmaker. Nat Immunol. 2011;12:715–23.CrossRef
9.
Zurück zum Zitat Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF kappa B collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 2010;21:11–9.CrossRef Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF kappa B collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 2010;21:11–9.CrossRef
10.
Zurück zum Zitat Gilmore TD, Gerondakis S. The c-REL transcription factor in development and disease. Genes Cancer. 2011;2:695–711.CrossRef Gilmore TD, Gerondakis S. The c-REL transcription factor in development and disease. Genes Cancer. 2011;2:695–711.CrossRef
11.
Zurück zum Zitat Wang Y, Rickman BH, Poutahidis T, et al. c-REL is essential for the development of innate and T cell-induced colitis. J Immunol. 2008;175:8118–255.CrossRef Wang Y, Rickman BH, Poutahidis T, et al. c-REL is essential for the development of innate and T cell-induced colitis. J Immunol. 2008;175:8118–255.CrossRef
12.
Zurück zum Zitat Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kB in diffuse large B-cell lymphoma. Nature. 2009;459:717–21.CrossRef Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kB in diffuse large B-cell lymphoma. Nature. 2009;459:717–21.CrossRef
13.
Zurück zum Zitat Hamoudi RA, Appert A, Ye H, et al. Differential expression of NF-kB target genes in MALT lymphoma with and without chromosome translocation: insights into molecular mechanism. Leukemia. 2010;24:1487–97.CrossRef Hamoudi RA, Appert A, Ye H, et al. Differential expression of NF-kB target genes in MALT lymphoma with and without chromosome translocation: insights into molecular mechanism. Leukemia. 2010;24:1487–97.CrossRef
14.
Zurück zum Zitat Geismann C, Grohmann F, Sebens S, et al. c-REL is a critical mediator of NF-kB dependent TRAIL resistance of pancreatic cancer cells. Cell Death Dis. 2014;5:e1455.CrossRef Geismann C, Grohmann F, Sebens S, et al. c-REL is a critical mediator of NF-kB dependent TRAIL resistance of pancreatic cancer cells. Cell Death Dis. 2014;5:e1455.CrossRef
15.
Zurück zum Zitat Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS Jr. Selective activation of NF-kB subunits in human breast cancer: potential roles for NF-kB2/p52 and for Bcl-3. Oncogene. 2000;19:1123–31.CrossRef Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS Jr. Selective activation of NF-kB subunits in human breast cancer: potential roles for NF-kB2/p52 and for Bcl-3. Oncogene. 2000;19:1123–31.CrossRef
16.
Zurück zum Zitat Gieling RG, Elsharkawy AM, Caamano JH, et al. The c-REL subunit of nuclear factor-kB regulates murine liver inflammation, wound-healing, and hepatocyte proliferation. Hepatology. 2010;51:922–31.CrossRef Gieling RG, Elsharkawy AM, Caamano JH, et al. The c-REL subunit of nuclear factor-kB regulates murine liver inflammation, wound-healing, and hepatocyte proliferation. Hepatology. 2010;51:922–31.CrossRef
17.
Zurück zum Zitat Elsharkawy AM, Mann DA. Nuclear factor-kB and the hepatic inflammation-fibrosis-cancer axis. Hepatology. 2007;46:590–7.CrossRef Elsharkawy AM, Mann DA. Nuclear factor-kB and the hepatic inflammation-fibrosis-cancer axis. Hepatology. 2007;46:590–7.CrossRef
18.
Zurück zum Zitat McNulty SE, del Rosario R, Cen D, Meyskens FL Jr, Yang S. Comparative expression of NFkappa B proteins in melanocytes of normal skin vs. benign intradermal naevus and human metastatic melanoma biopsies. Pigment Cell Res. 2004;17:173–180.CrossRef McNulty SE, del Rosario R, Cen D, Meyskens FL Jr, Yang S. Comparative expression of NFkappa B proteins in melanocytes of normal skin vs. benign intradermal naevus and human metastatic melanoma biopsies. Pigment Cell Res. 2004;17:173–180.CrossRef
19.
Zurück zum Zitat Wang Y, Rickman BH, Poutahidis T, et al. c-REL is essential for the development of innate and T cell-induced colitis. J Immunol. 2008;180:8118–255.CrossRef Wang Y, Rickman BH, Poutahidis T, et al. c-REL is essential for the development of innate and T cell-induced colitis. J Immunol. 2008;180:8118–255.CrossRef
20.
Zurück zum Zitat Gilmore TD, Gerondakis S. The c-REL transcription factor in development and disease. Genes Cancer. 2011;2:695–711.CrossRef Gilmore TD, Gerondakis S. The c-REL transcription factor in development and disease. Genes Cancer. 2011;2:695–711.CrossRef
21.
Zurück zum Zitat Lu YC, Kim I, Lye E, Shen F, Suzuki N, Suzuki S, Gerondakis S, Akira S, Gaffen SL, Yeh WC, Ohashi PS. Differential role for c-Rel and C/EBPbeta/delta in TLR-mediated induction of proinflammatory cytokines. J Immunol. 2009;182:7212–21.CrossRef Lu YC, Kim I, Lye E, Shen F, Suzuki N, Suzuki S, Gerondakis S, Akira S, Gaffen SL, Yeh WC, Ohashi PS. Differential role for c-Rel and C/EBPbeta/delta in TLR-mediated induction of proinflammatory cytokines. J Immunol. 2009;182:7212–21.CrossRef
22.
Zurück zum Zitat Dror R, Lederman M, Umezawa K, Barak V, Pe'er J, Chowers I. Characterizing the involvement of the nuclear factor-kappa B (NFκB) transcription factor in uveal melanoma. Invest Ophthalmol Vis Sci. 2010;51:1811–6.CrossRef Dror R, Lederman M, Umezawa K, Barak V, Pe'er J, Chowers I. Characterizing the involvement of the nuclear factor-kappa B (NFκB) transcription factor in uveal melanoma. Invest Ophthalmol Vis Sci. 2010;51:1811–6.CrossRef
23.
Zurück zum Zitat Liu N, Sun Q, Chen J, Li J, Zeng Y, Zhai S, Li P, Wang B, Wang X. MicroRNA-9 suppresses uveal melanoma cell migration and invasion through the NF-κB1 pathway. Oncol Rep. 2012;28:961–8.PubMed Liu N, Sun Q, Chen J, Li J, Zeng Y, Zhai S, Li P, Wang B, Wang X. MicroRNA-9 suppresses uveal melanoma cell migration and invasion through the NF-κB1 pathway. Oncol Rep. 2012;28:961–8.PubMed
24.
Zurück zum Zitat Makitie T, Summanen P, Tarkkanen A, Kivelä T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42(7):1414–21.PubMed Makitie T, Summanen P, Tarkkanen A, Kivelä T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42(7):1414–21.PubMed
25.
Zurück zum Zitat McLean IW, Foster WD, Zimmerman LE, Gamel JW. Modifications of Callender’s classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol. 1983;96:502–9.CrossRef McLean IW, Foster WD, Zimmerman LE, Gamel JW. Modifications of Callender’s classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol. 1983;96:502–9.CrossRef
26.
Zurück zum Zitat The AJCC Ophthalmic Oncology Task Force. International Validation of the American Joint Committee on Cancer’s 7th Edition Classification of Uveal Melanoma. JAMA Ophthalmol. 2015; 133: 376–383.CrossRef The AJCC Ophthalmic Oncology Task Force. International Validation of the American Joint Committee on Cancer’s 7th Edition Classification of Uveal Melanoma. JAMA Ophthalmol. 2015; 133: 376–383.CrossRef
27.
Zurück zum Zitat Li Z, Han C, Feng J. Relationship of the expression levels of XIAP and p53 genes in hepatocellular carcinoma and the prognosis of patients. Oncol Lett. 2017;14(4):4037–42.CrossRef Li Z, Han C, Feng J. Relationship of the expression levels of XIAP and p53 genes in hepatocellular carcinoma and the prognosis of patients. Oncol Lett. 2017;14(4):4037–42.CrossRef
28.
Zurück zum Zitat Rodig SJ, Savage KJ, LaCasce AS, et al. Expression of TRAF1 and nuclear c-REL distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma. Am J Surg Pathol. 2007;31:106–12.CrossRef Rodig SJ, Savage KJ, LaCasce AS, et al. Expression of TRAF1 and nuclear c-REL distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma. Am J Surg Pathol. 2007;31:106–12.CrossRef
29.
Zurück zum Zitat Tarlan B, Kıratlı H. Uveal melanoma: current trends in diagnosis and management. Turk J Ophthalmol. 2016;46:123–37.CrossRef Tarlan B, Kıratlı H. Uveal melanoma: current trends in diagnosis and management. Turk J Ophthalmol. 2016;46:123–37.CrossRef
30.
Zurück zum Zitat Shields CL, Shields JA, Kiratli H, De Potter P, Cater JR. Risk factors for growth and metastasis of small choroidal melanocytic lesions. Ophthalmology. 1995;102:1351–61.CrossRef Shields CL, Shields JA, Kiratli H, De Potter P, Cater JR. Risk factors for growth and metastasis of small choroidal melanocytic lesions. Ophthalmology. 1995;102:1351–61.CrossRef
31.
Zurück zum Zitat Shields CL, Furuta M, Thangappan A, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009;127:989–98.CrossRef Shields CL, Furuta M, Thangappan A, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009;127:989–98.CrossRef
32.
Zurück zum Zitat Diener-West M, Reynolds SM, Agugliaro DJ, et al. Collaborative Ocular Melanoma Study Group Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: collaborative ocular melanoma study group report no. 26. Arch Ophthalmol. 2005; 123: 1639–1643. Diener-West M, Reynolds SM, Agugliaro DJ, et al. Collaborative Ocular Melanoma Study Group Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: collaborative ocular melanoma study group report no. 26. Arch Ophthalmol. 2005; 123: 1639–1643.
33.
Zurück zum Zitat Singh AD, Shields CL, Shields JA. Prognostic factors in uveal melanoma. Melanoma Res. 2001;11:255–63.CrossRef Singh AD, Shields CL, Shields JA. Prognostic factors in uveal melanoma. Melanoma Res. 2001;11:255–63.CrossRef
34.
Zurück zum Zitat Jager MJ, Ly LV, El Filali M, et al. Macrophages in uveal melanoma and in experimental ocular tumor models: Friends or foes? Prog Retin Eye Res. 2011;30:129–46.CrossRef Jager MJ, Ly LV, El Filali M, et al. Macrophages in uveal melanoma and in experimental ocular tumor models: Friends or foes? Prog Retin Eye Res. 2011;30:129–46.CrossRef
35.
Zurück zum Zitat Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017; 2:17023. Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017; 2:17023.
36.
Zurück zum Zitat Terai M, Mastrangleo MJ, Sato T. Immunological aspect of the liver and metastatic uveal melanoma. J Cancer Metastasis Treat. 2017;3:231–43.CrossRef Terai M, Mastrangleo MJ, Sato T. Immunological aspect of the liver and metastatic uveal melanoma. J Cancer Metastasis Treat. 2017;3:231–43.CrossRef
37.
Zurück zum Zitat Weniger MA, Gesk S, Ehrlich S, et al. Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein. Gene Chromosome Cancer. 2007;46:406–15.CrossRef Weniger MA, Gesk S, Ehrlich S, et al. Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein. Gene Chromosome Cancer. 2007;46:406–15.CrossRef
38.
Zurück zum Zitat Li L, Xu-Monette ZY, Ok CY, Tzankov A, Manyam GC, Sun R, Visco C, Zhang M, et al. Prognostic impact of c-REL nuclear expression and REL amplification and crosstalk between c-REL and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget. 2015;15:23517–80. Li L, Xu-Monette ZY, Ok CY, Tzankov A, Manyam GC, Sun R, Visco C, Zhang M, et al. Prognostic impact of c-REL nuclear expression and REL amplification and crosstalk between c-REL and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget. 2015;15:23517–80.
39.
Zurück zum Zitat Barth TF, Martin-Subero JI, Joos S, et al. Gains of 2p involving the REL locus correlate with nuclear c-REL protein accumulation in neoplastic cells of classical Hodgkin lymphoma. Blood. 2003;101:3681–6.CrossRef Barth TF, Martin-Subero JI, Joos S, et al. Gains of 2p involving the REL locus correlate with nuclear c-REL protein accumulation in neoplastic cells of classical Hodgkin lymphoma. Blood. 2003;101:3681–6.CrossRef
40.
Zurück zum Zitat Curry CV, Ewton AA, Olsen RJ, et al. Prognostic impact of c-REL expression in diffuse large B-cell lymphoma. J Hematop. 2009;2:20–6.CrossRef Curry CV, Ewton AA, Olsen RJ, et al. Prognostic impact of c-REL expression in diffuse large B-cell lymphoma. J Hematop. 2009;2:20–6.CrossRef
Metadaten
Titel
Constitutive expression of c-REL in uveal melanoma patients: correlation with clinicopathological parameters and patient outcome
verfasst von
M. K. Singh
L. Singh
N. Pushker
K. Chosdol
S. Bakhshi
R. Meel
S. Sen
S. Kashyap
Publikationsdatum
25.11.2019
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 7/2020
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02247-z

Weitere Artikel der Ausgabe 7/2020

Clinical and Translational Oncology 7/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.